INTRODUCTION
It is commonly accepted that the immunogenicity of foot and mouth disease (FMD) vaccines is dependent on the presence of the intact capsid, as either the nucleocapsid with a sedimentation rate of 140S or the natural empty particle which sediments at 75S (10, 15, 20, 37, 40, 44) . For the majority of strains, the principal immunogenic component is the 140S particle. Several studies have shown a direct relationship between the dose of 140S antigen in vaccine lots and the rate, height and persistence of virus neutralising antibody in cattle after both primary and secondary vaccination (8, 9, 29, 30, 34, 39) . Hence many modern FMD vaccine manufacturing establishments include the quantification of 140S antigen in the battery of quality control tests during production (5, 21, 22, 26, 31, 34, 38, 42) .
There are conflicting reports in the literature on the effect of commonly used virus inactivators, formaldehyde and aziridine compounds, on the integrity of FMD virus capsid and thereby on immunogenicity. Formaldehyde has been largely discredited as an inactivator, mainly because of non-linear inactivation kinetics leading to residual infective virus which, sometimes, is detectable for several weeks after completion of the "inactivation" period of 48 hours (12, 19, 41) . There have been several instances of FMD outbreaks considered to have been associated with the use of formaldehydeinactivated vaccines (7) . In contrast, the aziridine compounds acetylethyleneimine (12) , ethyleneimine (17) and binary ethyleneimine (3) have been associated with firstorder virus inactivation kinetics and have, generally, resulted in innocuous vaccines. Such compounds fulfil a recent recommendation by the OIE for inactivated FMD vaccines (33) .
Nevertheless, some reports in the literature have claimed that both formaldehyde (27) and aziridine compounds (36) are able to destroy the FMD virus capsid and thereby reduce vaccine immunogenicity. At Pirbright (32, 36) , a hybrid inactivation procedure involving sequential treatment of virus with formaldehyde and AEI was devised in order to preserve the 140S particle. As far as we know, the method is not widely employed by FMD vaccine manufacturers.
In the present study we investigated the effect of formaldehyde and binary ethyleneimine on South American strains of FMD virus capsid when the compounds were used either singly or in sequence.
MATERIALS AND METHODS

Virus strains
The strains of FMDV used in this study were all of South American origin: O Campos/Brasil-58, A Cruzeiro/Brasil-55, A Venceslau/Brasil-76, A Bagé/Brasil-76, A Castellano/Argentina-87 and C Indaial/Brasil-71. They had been adapted to growth in BHK suspension cells (14) for vaccine production. For this study each virus was grown in BHK suspension cells either in a spinner culture of 2 litre volume or in a 3000 litre fermenter. Virus was harvested at maximum cytopathic effect (c.p.e.), usually after 16 to 24 h.
Inactivation with formaldehyde
The virus suspension was adjusted to pH 8.0 with glycine buffer and a temperature of 26°C in a water-bath fitted with a magnetic stirrer. Then 1:10 formalin in distilled water was added to the virus suspension to a final concentration of 0.06% v/v formalin. Periodically the virus-containing flask was manually inverted in order to bring virus in the air space above the liquid level (less than 10% of total flask capacity) into contact with inactivator. Inactivation proceeded for 48 h under magnetic agitation.
Inactivation with BEI
The procedure adopted was similar to that described by Bahnemann (3) . BEI was generated by treating 0.1M 2-bromoethylamine hydrobromide with 0.2N NaOH for 1 hour at 37°C. This solution was then added to the virus suspension to give the desired concentration of BEI, i.e. 1% v/v for 1mM BEI; 2% v/v for 2mM BEI, etc. Periodically, the virus-containing bottle was inverted in order to inactivate virus in the air space above the liquid level. Temperature and time of inactivation were as specified under "Results". Excess BEI was neutralised at the end of the inactivation period with 0.1% w/v sodium thiosulphate.
Inactivation kinetics and innocuity testing
For measuring inactivation kinetics, samples were collected at hourly intervals up to 4 h after adding inactivator. The inactivator was neutralised and samples titrated for surviving virus infectivity by using the microcolour test (28) . The kinetics constant, slope and half-life were calculated.
At 24 and 48 hours after commencement of inactivation, samples were collected for innocuity testing. After neutralisation, each sample was inoculated onto duplicate Roux flasks of BHK monolayers maintained on a serum-free medium. The cultures were examined for c.p.e. and complement fixing antigen over three serial passages (2, 16) .
Quantification of 140S
Test virus samples were first concentrated tenfold by using saturated ammonium sulphate either at 4°C overnight or at room temperature (ca. 25°C) for two hours, and resuspended in 0.04M phosphate buffer. Then the concentration of the 140S particles was assayed by sucrose density gradient using the methods of Barteling and Meloen (5) and Doel et al. (21) . Briefly, the sample was treated with 0.001% (w/v) bovine ribonuclease at 36°C for 10 min to degrade any free RNA or ribosome, and then 1 ml of this was layered onto a preformed, linear 10-30% (w/v) sucrose density gradient. The gradients were centrifuged at 40,000 rpm using the Beckmann SW 41 Ti rotor in the Beckmann L8-55M ultracentrifuge for 60 min. Then the gradients were scanned at 259 nm wavelength using the Beckmann DU-7U spectrophotometer fitted with a continuous 0.2 cm pathlength flow-cell. The area under the peak was calculated and used to determine the concentration of 140S particles using the following formula: Under our conditions the method gives a coefficient of variation of 12% for intertest and 5% for intra-test variation.
Statistical analysis
The statistical analysis of data was carried out using the RS/1 programme of BBN Software Products Corporation (Cambridge, USA) operating in the DOS mode of IBM on the Microtec XT 2002 microcomputer. The level of rejection of the null hypothesis was set at 0.05.
RESULTS
Lot no.
Live Two series of experiments were carried out. In the first the virus harvest was divided into four lots: one lot was inactivated with formaldehyde (0.06% v/v formalin); the second was inactivated with two doses of 1mM BEI 24 hours apart; the third was treated for the first 24 hours with formaldehyde and then, additionally, with 1mM BEI; the fourth lot was left as a live virus control. The pH of all 4 lots was adjusted to pH 8.0 and they were all incubated under agitation in the same water-bath at 26°C for a total of 48 hours. For each virus strain 4-6 replicate tests were thus carried out.
The results of this set of experiments are summarised in Table I a-d and Figure  1 , from which it is evident that the reduction in 140S level due to BEI treatment was less than 25% and statistically insignificant for any of the tested strains. In contrast, formaldehyde, either alone or in combination with BEI, reduced 140S by up to 72%. This reduction was evidently primarily due to the action of formaldehyde. By one way analysis of variance the reduction in 140S level caused by formaldehyde was shown to be significant for strains O Campos and A Cruzeiro (p < 0.05).
TABLE la
Effect of inactivators on concentration of 140S antigen (µg/ml) in vaccine virus harvests of strain O Campos
Formaldehyde versus BEI on FMDV 140S particle In the second set of experiments a direct comparison was made of formaldehyde plus BEI treatment versus BEI alone. For each strain 8-10 replicate sets of inactivations were carried out. The results are summarised in Table II and Figure 2 . The statistical analysis hypothesis investigated was whether the residual 140S concentration was significantly lower after formaldehyde than after BEI treatment, as the first set of experiments had already indicated a destructive effect for formaldehyde. Therefore, a one-tailed t-test was applied to the data.
It was demonstrated for five of the six South American virus strains tested that formaldehyde significantly reduced the concentration of 140S particles.
Effect of formaldehyde on stability of stored virus
Pairs of eight lots of harvested virus inactivated either with BEI alone (ImM x 2 for 48 hours) or formaldehyde plus BEI (as described above) were stored at 3-6°C for six months. They were assayed for 140S content at the beginning and end of the storage period. 
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Effect of formaldehyde and BEI on FMDV 140S concentration
The results obtained are summarised in Table III . For BEI inactivated samples, there was no significant drop in the 140S level over the study period. However, the formaldehyde-treated samples had shown a 33-85% reduction in 140S level; this decay was shown to be statistically significant by the one-tailed t-test (p < 0.05). 
Effect of temperature of BEI inactivation on 140S particles
FMDV inactivation with BEI is usually carried out at 35-37°C with a concentration of 1.0-1.5mM applied either once for 24 hours or repeated for an additional 24 hour period (i.e. total 48 h). A recent report by Bahnemann et al. (4) implied that the virus breaks down under these conditions, and these authors adopted a higher dose of BEI (3mM) at 26°C for only 24 h. Two sets of experiments were carried out to investigate this. In the first set, for each virus strain, 5-15 lots of harvest were inactivated in parallel either by one dose of 3mM BEI at 26°C for 48 hours or by 2 doses each of 1mM BEI at 36°C with the second dose after the initial 24 hours. Results of 140S assay are shown in Table  IV and Figure 3 from which it can be deduced that no significant difference was detected between the lower BEI dose at 36°C and the higher BEI dose at 26°C (p > 0.3).
In the second set of experiments comparison was made of 3mM BEI at 26°C with 3mM at 36°C for a total period of 48 h. In each case a single dose was applied. Each virus strain was thus tested in ten replicates with different virus harvests. Results are summarised in Table V . There was no significant difference in the level of 140S detected after inactivation at either temperature (p > 0.7), although in general there was a tendency for slightly lower values at 36°C after 48 hours than at 26°C.
Efficiency of inactivation of virus infectivity by different BEI procedures
BEI was tested in concentrations of l-3mM at 26°C or 36°C over 48-hour periods. Samples for inactivation kinetics titration were collected at times 0, 1, 2, 3, 4 hours and for innocuity testing in BHK monolayer cells at 24 and 48 hours. The results are summarised in Tables VI and VII . When BEI inactivation was performed at 26°C, regardless of concentration, or at a concentration of 1mM regardless of temperature, there-was a risk of incomplete inactivation of virus infectivity. Procedures at 36°C with BEI doses of 2mM or above were found to be safe in terms of FMDV innocuity.
Effect of temperature and BEI dose on FMDV 140S concentration
DISCUSSION
Aziridine compounds are efficient inactivators of FMD virus for vaccine manufacture (24, 35) . However, workers at Pirbright demonstrated that certain strains of serotype SAT 2 were particularly labile to acetylethyleneimine, and that this destructive effect of AEI could be overcome by pre-fixing the virus with formaldehyde (32, 36) . It seemed possible, therefore, that the stability of FMDV vaccines would be improved by always treating virus harvests with formaldehyde before complete inactivation with an aziridine compound, such as BEI. However, several studies had indicated that formaldehyde itself might be deleterious to some strains of FMDV. For example, Wild and Brown (44) observed that although formaldehyde-inactivated FMD virus sedimented at 140S, its immunising activity for guinea pigs was much lower than the AEI inactivated preparation. Girard et al. (27) found that by using BEI, instead of formalin, to inactivate a strain of type O virus from Turkey, there was a marked improvement in the potency for cattle of the corresponding vaccine. Adamowicz et al. (1) demonstrated that formaldehyde degraded the 140S particles of types O and C virus but not type A. In a more recent study, Ferris et al. (25) found that formaldehyde had a variable effect on 140S particles, depending on virus strain: it stabilised a strain of serotype SAT 2, had little influence on the 140S of some strains, produced a reduction of 140S for some and totally degraded other strains (e.g. A France 1/68). In several cases these authors also observed that pretreatment of virus with formaldehyde resulted in antigens of reduced immunogenicity for guinea pigs.
Most of these studies, however, were based on a limited number of observations and often there was no statistical analysis of the observed effect. In the present study, an attempt was made to obtain data from statistically analysable sets of replicates. By so doing, we have shown that 5 of 6 South American strains of FMDV, of serotypes O, A, C, suffered a significant reduction in 140S compared with intact virus or virus inactivated with BEI. The exception was strain A Bagé, which was not significantly susceptible to the action of formaldehyde. Further, we have shown that upon storage at 4°C, formaldehyde-treated 140S particles degrade significantly over six months in contrast to BEI-treated virus. Ferris et al. (25) found that only strain C Resende decayed upon storage at 4°C. But in agreement with our results is the work of Czelleng et al. (18) who found that of the virus strains studied, there was only 3-30% residual complement fixing activity after a storage period of five weeks. Therefore, it can be concluded that far from being a general stabilising agent, formaldehyde can often degrade the immunising antigen (140S particles) of FMDV.
These observations would seem to be at variance with the general experience by users of formalin who claim high potency for formaldehyde-inactivated antigen. The apparent anomaly is probably explicable on the following grounds. Firstly, such claims may express sentiment more than experimental evidence. Secondly, because of the curvilinear inactivation kinetics by formaldehyde, it is quite probable that some residual live virus in the vaccine could contribute to the potency of antigens inactivated only with formaldehyde. Thirdly, it can be argued that adsorption of virus onto aluminium hydroxide before inactivation might preserve the virus capsid from the destructive effects of formaldehyde. However, in their re-evaluation of FMD inactivation by formaldehyde, Barteling and Woortmeyer (6) did not confirm this preserving effect of aluminium hydroxide. It should be noted that with adsorbed antigen, it is difficult to quantify effects on 140S owing to the inefficiency of quantitative elution of virus from aluminium hydroxide (23, 41, 43) . A further explanation of why the deleterious effects of formaldehyde on virus capsid may not become readily apparent in routine potency tests, lies in the fact that the relationship between antigen dose and antibody response for FMD vaccines is sigmoid rather than linear (9, 39) . The effect of changes in antigen content can be masked by responses being in the upper plateau of the sigmoid curve.
Finally our studies with BEI have shown that concentration (l-3mM) and temperature of virus inactivation (26°C or 36°C) are important for complete inactivation of infectivity, but probably not as critical as indicated by the observation of Bahnemann (4) in terms of 140S particle integrity. We have not been able to confirm his observation of thermal lability of South American FMDV strains at 36°C within 24 hours. Our results agree with those of Brown and others (11, 13) who showed that at 37°C FMD virus loses infectivity on account of in situ RNA degeneration, but without breakdown of the capsid into sub-units. It is probable that culture constituents or environmental conditions, other than temperature, or the quality of the primary chemical, bromoethylamine, or the efficiency of its conversion to BEI may be more critical in the effect of inactivation on the 140S particle than simply temperature (26°C or 36°C) per se. It is important, therefore, that these parameters be standardised within the production environment of a vaccine manufacturer. 
*
